The role of procalcitonin in community-acquired pneumonia: A literature review

Advanced Emergency Nursing Journal

Volumn 34, Issue 3, 2012, Pages 259-271

  Lee, Mijung ^a   Snyder, Audrey ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

community acquired pneumonia; procalcitonin

Indexed keywords

BIOLOGICAL MARKER; CALCITONIN; PROCALCITONIN; PROTEIN PRECURSOR;

BACTERIAL PNEUMONIA; COMMUNICABLE DISEASE; HOSPITALIZATION; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

BIOLOGICAL MARKERS; CALCITONIN; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; PNEUMONIA, BACTERIAL; PROTEIN PRECURSORS; SEVERITY OF ILLNESS INDEX;

EID: 84864566469     PISSN: 19314485     EISSN: None     Source Type: Journal    
DOI: 10.1097/TME.0b013e318261338d     Document Type: Review

References (48)

1. Al-Nawas, B., Krammer, I., & Shah, P. M. (1996). Procalcitonin in diagnosis of severe infections. European Journal of Medical Research, 1(7), 331-333.
2. Annane, D., Bellissant, E., & Cavaillon, J. M. (2005). Septic shock. Lancet, 365(9453), 63-78.
3. Aujesky, D., Stone, R. A., Obrosky, D. S., Yealy, D. M., Auble, T. E., Meehan, T. P., Fine,M. J. (2005). Using randomized controlled trial data, the agreement between retrospectively and prospectively collected data comprising the pneumonia severity index was substantial. Journal of Clinical Epidemiology, 58(4), 357-363. doi:10.1016/j.jclinepi.2004.08.011 (Pubitemid 40601983)
4. Bellmann-Weiler, R., Ausserwinkler, M., Kurz, K., Theurl, I., & Weiss, G. (2010). Clinical potential of Creactive protein and procalcitonin serum concentrations to guide differential diagnosis and clinical management of pneumococcal and Legionella pneumonia. Journal of Clinical Microbiology, 48(5), 1915-1917.
5. Boussekey, N., Leroy, O., Georges, H., Devos, P., d'Escrivan, T., & Guery, B. (2005). Diagnostic and prognostic values of admission procalcitonin levels in community-acquired pneumonia in an intensive care unit. Infection, 33(4), 257-263. BRAHMS. (n.d.). PCT. Retrieved from http://www. procalcitonin.com/ (Pubitemid 41152186)
6. Briel, M., Schuetz, P., Mueller, B., Young, J., Schild, U., Nusbaumer, C., Christ-Crain, M. (2008). Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Archives of Internal Medicine, 168(18), 2000-2007.
7. Brown, J. S. (2009). Biomarkers and community-acquired pneumonia. Thorax, 64(7), 556-558.
8. Brown, S. M., & Dean, N. C. (2010). Defining and predicting severe community-acquired pneumonia. Current Opinion in Infectious Diseases, 23(2), 158-164. doi:10.1097/QCO.0b013e3283368333
9. Charles, P. E., Tinel, C., Barbar, S., Aho, S., Prin, S., Doise, J. M., Quenot, J. P. (2009). Procalcitonin kinetics within the first days of sepsis: Relationship with the appropriateness of antibiotic therapy and the outcome. Critical Care, 13(2), R38.
10. Christ-Crain, M., Jaccard-Stolz, D., Bingisser, R., Gencay, M. M., Huber, P. R., Tamm, M., M̈uller, B. (2004). Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: Cluster-randomised, single-blinded intervention trial. Lancet, 363(9409), 600-607. (Pubitemid 38264177)
11. Chris-Crain, M., & M̈uller, B. (2007). Procalcitonin and pneumonia: Is it a useful marker? Current Infectious Disease Reports, 9(3), 233-240. (Pubitemid 46736261)
12. Christ-Crain, M., Stolz, D., Bingisser, R., M̈uller, C., Miedinger, D., Huber, P. R., M̈uller, B. (2006). Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: A randomized trial. American Journal of Respiratory and Critical Care Medicine, 174(1), 84-93. (Pubitemid 43955248)
13. Clec'h, C., Ferriere, F., Karoubi, P., Fosse, J. P., Cupa, M., Hoang, P., Cohen, Y. (2004). Diagnostic and prognostic value of procalcitonin in patients with septic shock. Critical Care Medicine, 32(5), 1166-1169. (Pubitemid 38620986)
14. Donowitz, G. R. (2010). Acute pneumonia. In G. L. Mandell, J. E. Bennett, & R. Dolin (Eds.), Mandell, Douglas, and Bennett's principles and practice of infectious disease (7th ed., pp. 891-916). Philadelphia, PA: Churchill Livingstone Elsevier.
15. Fang, G. D., Find, M., Orloff, J., Arisumi, D., Yu, V. L., Kapoor,W.,Muder, R. R. (1990). New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine (Baltimore), 69(5), 307-316. (Pubitemid 20360038)
16. File, T. M., & Marrie, T. J. (2010). Burden of communityacquired pneumonia in North American adults. Postgraduate Medical Journal, 122(2), 130-141.
17. Giamarellos-Bourboulis, E. J., Giannopoulou, P., Grecka, D. V., Voros, D., Mandragos, K., & Giamarellow, H. (2004). Should Procalcitonin be introduced in the diagnostic criteria for the systemic inflammatory response syndrome and sepsis? Journal of Critical Care, 19(3), 152-157. (Pubitemid 39299181)
18. Hedlund, J., & Hansson, L. O. (2000). Procalcitonin and Creactive protein levels in community-acquired pneumonia: Correlation with etiology and prognosis. Infection, 28(2), 68-73. (Pubitemid 30189610)
19. Heron, M., Hoyert, D. L., Murphy, S. L., Xu, J., Kochanek, K. D., & Tejada-Vera, B. (2009). Deaths: Final data for 2006. National Vital Statistics Reports, 57(14), 1-135. Retrieved from http://www.cdc.gov/nchs/data/nvsr/nvsr57/ nvsr57 14.pdf
20. Hirakata, Y., Yanagihara, K., Kurihara, S., Izumikawa, K., Seki, M., Miyazaki, Y., Kohno, S. (2008). Comparison of usefulness of plasma procalcitonin and C-reactive protein measurements for estimation of severity in adults with community-acquired pneumonia. Diagnostic Microbiology and Infectious Disease, 61, 170-174. doi:10.1016/j.diagmicrobio.2008.01.014 (Pubitemid 351680368)
21. Huang, D. T., Weissfeld, L. A., Kellum, J. A., Yealy, D. M., Kong, L., Martino, M.,. Angus, D. C. (2008). Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Annals of Emergency Medicine, 52(1), 48-58.e2. doi:10.1016/j.annemergmed.2008.01.003
22. Jacobs, J. W., Lund, P. K., Potts, J. T., Bell, N. H., & Habener, J. F. (1981). Procalcitonin is a glycoprotein. The Journal of Biological Chemistry, 256(6), 2803-2807. (Pubitemid 11125087)
23. Jereb, M., & Kotar, T. (2006). Usefulness of procalcitonin to differentiate typical from atypical communityacquired pneumonia. Wiener Klinische Wochenschrift, 118(5-6), 170-174. doi:10.1007/s00508-006-0563-8 (Pubitemid 43666698)
24. Kaplan, V., Clermont, G., Griffin, M. F., Kasal, J., Watson, R. S., Linde-Zwirble, W. T., Angus, D. C. (2003). Pneumonia: Still the old man's friend? Archives of Internal Medicine, 163(3), 317-323. (Pubitemid 36183860)
25. Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1985). APACHE II: A severity of disease classification system. Critical Care Medicine, 13(10), 818-829. (Pubitemid 15250137)
26. Kr̈uger, S., Ewig, S., Giersdorf, S., Hartmann, O., Suttorp, N., & Welte, T. (2010). Cardiovascular and inflammatory biomarkers to predict short-and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ. American Journal of Respiratory and Critical Care Medicine, 182(11), 1426-1434.
27. Kr̈uger, S., Ewig, S., Kunde, J., Hartmann, O., Suttorp, N., & Welte, T. (2010). Pro-atrial natriuretic peptide and pro-vasopressin for predicting short-term and long-term survival in communityacquired pneumonia: Results from the German Competence Network CAPNETZ. Thorax, 65(3), 208-214. doi:10.1136/thx.2009.121178
28. Kr̈uger, S., Ewig, S., Marre, R., Papassotiriou, J., Richter, K., von Baum, H., Welte, T. (2008). Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. European Respiratory Journal, 31(2), 349-355. doi:10.1183/09031936.00054507
29. Levy, M. M., Fink, M. P., Marshall, J. C., Abraham, E., Angus, D., Cook, D., Ramsay, G. (2003). 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Critical Care Medicine, 31(4), 1250-1256. (Pubitemid 36444440)
30. Lim, W. S., van der Eerden, M. M., Laing, R., Boersma, W. G., Karalus, N., Town, G. I.,Macfarlane, J. T. (2003). Defining community acquired pneumonia severity on presentation to hospital: An international derivation and validation study. Thorax, 58(5), 377-382. (Pubitemid 36560938)
31. Mandell, L. A., Wunderink, R. G., Anzueto, A., Bartlett, J. G., Campbell, G. D., Dean, N. C., Whitney, C. G. (2007). Infectious Diseases Society of America/American Thoracic Society consensus guidelines on themanagement of community-acquired pneumonia in adults. Clinical Infectious Disease, 44(Suppl. 2), S27-S72. (Pubitemid 46290553)
32. Masía, M., Guti ́errez, F., Shum, C., Padilla, S., Navarro, J., Flores, E., Herńandez, I. (2005). Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest, 128(4), 2223-2229. (Pubitemid 41507563)
33. Meńendez, R., Mart́nez, R., Reyes, S., Mensa, J., Filella, X., Marcos, M. A., Torres, A. (2009). Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax, 64(7), 587-591. doi:10.1136/thx.2008.105312
34. Minino, A. M., Heron, M. P., & Smith, B. L. (2006). Death: Preliminary data for 2004. National Vital Statistics Report, 54(19), 1-49.
35. Mira, J. P., Max, A., & Burgel, P. R. (2008). The role of biomarkers in community-acquired pneumonia: Predicting mortality and response to adjunctive therapy. Critical Care, 12(Suppl. 6), S5. doi:10.1186/cc 7028
36. M̈uller, B., Peri, G., Doni, A., Perruchoud, A. P., Landmann, R., Pasqualini, F., Mantovani, A. (2002). High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: Association of high decoy receptor levels with glucocorticoid administration. Journal of Leukocyte Biology, 72(4), 643-649. (Pubitemid 36277834)
37. Nazarian, D. J., Eddy, O. L., Lukens, T. W., Weingart, S. D., & Decker, W. W. (2009). Clinical policy: Critical issues in the management of adult patients presenting to the emergency department with community-acquired pneumonia. Annals of Emergency Medicine, 54(5), 704-731.
38. Niederman, M. S. (2008). Biologicalmarkers to determine eligibility in trials for community-acquired pneumonia: A focus on procalcitonin. Clinical Infectious Disease, 47(Suppl. 3), S127-S131.
39. Nijsten, N. W., Olinga, P., The, T. H., de Vries, E. G., Koops, H. S., Groothuis, G. M., Zwaveling, J. H. (2000). Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Critical Care Medicine, 28(2), 458-461. (Pubitemid 30120889)
40. Rello, J. (2008). Demographics, guidelines and clinical experience in severe community-acquired pneumonia. Critical Care, 12(Suppl. 6), S2. doi:10.1186/cc7025
41. Riedel, S., Melendez, J. H., An, A. T., Rosenbaum, J. E., & Zenilman, J. M. (2011). Procalcitonin as a marker for the detection of bacteremia and sepsis in the emergency department. American Journal of Clinical Pathology, 135(2), 182-189.
42. Schuetz, P., Briel, M., Christ-Crain, M., Wolbers, M., Stolz, D., Tamm, M.,. M̈uller, B. (2009). Procalcitonin to initiate or withhold antibiotics in acute respiratory tract infections (Protocol). The Cochrane Collaboration, (3), 1-7.
43. Schuetz, P., Chiappa, V., Briel, M., & Greenwald, J. L. (2011). Procalcitonin algorithms for antibiotic therapy decisions: A systematic review of randomized controlled trials and recommendations for clinical algorithms. Archives of Internal Medicine, 171(15), 1322-1331.
44. Simon, L., Gauvin, F., Amre, D. K., Saint-Louis, P., & Lacroix, J. (2004). Serum procalcitonin and Creactive levels as markers of bacterial infection: A systemic review and meta-analysis. Clinical Infectious Disease, 39(2), 206-217. (Pubitemid 38971491)
45. Uzzan, B., Cohen, R., Nicolas, P., Cucherat, M., & Perret, G. Y. (2006). Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: A systematic review and meta-analysis. Critical Care Medicine, 34(7), 1996-2003. (Pubitemid 43982479)
46. Whang, K. T., Steinwald, P. M., White, J. C., Nylen, E. S., Snider, R. H., Simon, G. L., Becker, K. L. (1998). Serum calcitonin precursors in sepsis and systemic inflammation. The Journal of Clinical Endocrinology and Metabolism, 83(9), 3296-3301. doi:10.1210/jc.83.9.3296 (Pubitemid 28500975)
47. Yealy, D. M., Auble, T. E., Stone, R. A., Lave, J. R., Meehan, T. P., Graff, L. G., Fine, M. J. (2004). The emergency department community-acquired pneumonia trial: Methodology of a quality improvement intervention. Annals of Emergency Medicine, 43(6), 770-782. (Pubitemid 38697502)
48. Zahorec, R. (2011).Definition for septic syndrome should be re-evaluated. Intensive Care Medicine, 26(12), 1870.